CR20110267A - Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma - Google Patents

Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma

Info

Publication number
CR20110267A
CR20110267A CR20110267A CR20110267A CR20110267A CR 20110267 A CR20110267 A CR 20110267A CR 20110267 A CR20110267 A CR 20110267A CR 20110267 A CR20110267 A CR 20110267A CR 20110267 A CR20110267 A CR 20110267A
Authority
CR
Costa Rica
Prior art keywords
quinuclidin
carboxamide
benzo
thiophen
chlorine
Prior art date
Application number
CR20110267A
Other languages
English (en)
Inventor
Gerhard Koenig
Richard Chesworth
Gideon Shapiro
Original Assignee
Envivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Envivo Pharmaceuticals Inc filed Critical Envivo Pharmaceuticals Inc
Publication of CR20110267A publication Critical patent/CR20110267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se ha encontrado que la (R)-7-cloro-N-(quinuclidin-3-il)benzo[]tiofeno-2-carboxamida tiene efectos procognitivos en humanos en dosis inesperadamente bajas.
CR20110267A 2008-11-19 2011-05-20 Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma CR20110267A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11610608P 2008-11-19 2008-11-19

Publications (1)

Publication Number Publication Date
CR20110267A true CR20110267A (es) 2011-10-13

Family

ID=41786120

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110267A CR20110267A (es) 2008-11-19 2011-05-20 Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma

Country Status (35)

Country Link
US (6) US8642638B2 (es)
EP (4) EP3357495B1 (es)
JP (6) JP5272080B2 (es)
KR (3) KR20180011888A (es)
CN (3) CN102281878A (es)
AU (1) AU2009316557B2 (es)
BR (1) BRPI0922057A2 (es)
CA (3) CA2894860C (es)
CL (3) CL2011001178A1 (es)
CO (1) CO6400190A2 (es)
CR (1) CR20110267A (es)
CY (3) CY1113671T1 (es)
DK (3) DK2540297T3 (es)
EC (1) ECSP11011076A (es)
ES (3) ES2673016T3 (es)
HK (1) HK1158520A1 (es)
HR (3) HRP20130007T1 (es)
HU (2) HUE026815T2 (es)
IL (5) IL212921A (es)
LT (1) LT2889033T (es)
MX (1) MX2011005270A (es)
MY (2) MY159826A (es)
NZ (2) NZ613291A (es)
PE (1) PE20110711A1 (es)
PH (2) PH12014501629B1 (es)
PL (3) PL2355822T3 (es)
PT (3) PT2540297E (es)
RS (1) RS52583B (es)
RU (3) RU2532327C2 (es)
SG (1) SG10201504102QA (es)
SI (3) SI2889033T1 (es)
SM (2) SMT201300003B (es)
TR (1) TR201807944T4 (es)
WO (1) WO2010059844A1 (es)
ZA (1) ZA201104044B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DK2540297T3 (en) 2008-11-19 2015-07-13 Forum Pharmaceuticals Inc The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CR20170556A (es) 2010-05-17 2018-02-27 Forum Pharmaceuticals Inc UNA FORMA CRISTALINA DE CLORHIDRATO DE (R)-7-CLORO-N-(QUINUCLIDIN-3-IL) BENZO[B] TIOFENO-2-CARBOXAMIDA MONOHIDRATO (Divisional 2012-0585)
EP2640378A4 (en) * 2010-11-18 2014-05-21 Envivo Pharmaceuticals Inc INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS
WO2012154710A1 (en) * 2011-05-09 2012-11-15 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
CA2840746A1 (en) * 2011-07-01 2013-01-10 Envivo Pharmaceuticals, Inc. Methods of treatment of limited cognitive impairment
AU2013259871A1 (en) * 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
WO2018156202A1 (en) 2017-02-27 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-psychotic composition and treatment methods
EP3684463A4 (en) 2017-09-19 2021-06-23 Neuroenhancement Lab, LLC NEURO-ACTIVATION PROCESS AND APPARATUS
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
WO2019133997A1 (en) 2017-12-31 2019-07-04 Neuroenhancement Lab, LLC System and method for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3849410A4 (en) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC SLEEP ENHANCEMENT SYSTEM AND METHOD

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (de) 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de) 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
US4985420A (en) 1987-12-10 1991-01-15 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and -amides
US5198437A (en) 1987-12-10 1993-03-30 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and amides
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en) 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5114947A (en) 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de) 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
PL183933B1 (pl) 1994-08-24 2002-08-30 Astra Ab Związki spiroazabicyklo, sposób wytwarzania związku spiroazabicyklo i kompozycja farmaceutyczna
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
FR2756826B1 (fr) 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU745964B2 (en) 1997-05-30 2002-04-11 Neurosearch A/S 8-Azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
EP1114153A2 (en) 1998-09-18 2001-07-11 The Rockefeller University Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en) 1999-11-08 2002-07-09 Research Triangle Institute Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
JP2003530542A (ja) 1999-12-01 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経変性疾患の診断方法
CA2393538A1 (en) 1999-12-14 2001-06-21 Pharmacia & Upjohn Company Human ion channels
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr) 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10044905A1 (de) 2000-09-12 2002-03-21 Merck Patent Gmbh (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
ES2275808T3 (es) 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005504059A (ja) 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
JP2003081978A (ja) 2001-09-10 2003-03-19 Mitsubishi Pharma Corp スピロ環式化合物およびその医薬用途
JP2005527472A (ja) 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
EA007429B1 (ru) 2001-10-02 2006-10-27 Фармация Энд Апджон Компани Азабициклические замещённые конденсированные гетероарильные соединения
WO2003037896A1 (en) 2001-10-26 2003-05-08 Pharmacia & Upjohn Company N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
EP1442041A1 (en) 2001-11-08 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
CA2466344A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
FR2832714B1 (fr) 2001-11-23 2004-07-16 Sanofi Synthelabo Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
EP1463481A4 (en) 2001-12-14 2008-06-25 Targacept Inc METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10162442A1 (de) 2001-12-19 2003-07-03 Bayer Ag Monocyclische N-Aryl-amide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2476417A1 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
WO2003070731A2 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
AU2003219690A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7358057B2 (en) 2002-05-09 2008-04-15 Memory Pharmaceuticals Corporation QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
BR0312736A (pt) 2002-07-17 2005-04-26 Warner Lambert Co Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
JP2006510662A (ja) 2002-12-11 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
KR101176670B1 (ko) 2004-03-25 2012-08-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도
KR20080048550A (ko) 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
ATE540954T1 (de) 2007-05-11 2012-01-15 Pfizer Aminoheterocyclische verbindungen
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
WO2009028588A1 (ja) 2007-08-31 2009-03-05 Eisai R & D Management Co., Ltd. 多環式化合物
CA2701126A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, and pharmaceutical uses thereof
BRPI0820418A2 (pt) 2007-11-21 2015-05-19 Abbott Lab "derivados de alcano azabicíclico substituído com biarila como moduladores da atividade do receptor nicotínico de acetilcolina"
AU2009242126B2 (en) 2008-04-29 2014-03-27 Pharnext New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis
MX2010011880A (es) 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
BRPI0911874A2 (pt) 2008-04-29 2018-05-22 Pharnext composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
CN102369202A (zh) 2008-11-13 2012-03-07 链接医药公司 氮杂喹啉酮衍生物及其应用
DK2540297T3 (en) 2008-11-19 2015-07-13 Forum Pharmaceuticals Inc The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
EP2381955A4 (en) 2008-12-30 2013-01-16 Univ Ramot COMBINATION THERAPIES WITH NAP
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
CN102395371A (zh) 2009-04-13 2012-03-28 施万制药 用于治疗认知障碍的5-ht4受体促效剂化合物
CN102548986A (zh) 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions

Also Published As

Publication number Publication date
US8642638B2 (en) 2014-02-04
DK2355822T3 (da) 2013-01-28
EP2889033B1 (en) 2018-03-21
SI2540297T1 (sl) 2015-08-31
AU2009316557B2 (en) 2015-08-27
RU2018125456A (ru) 2020-01-13
JP5869653B2 (ja) 2016-02-24
EP2355822B1 (en) 2012-10-10
EP3357495A1 (en) 2018-08-08
KR20110091549A (ko) 2011-08-11
PL2355822T3 (pl) 2013-03-29
CA2894860A1 (en) 2010-05-27
JP2012509347A (ja) 2012-04-19
EP2540297A1 (en) 2013-01-02
CL2011001178A1 (es) 2011-10-14
CY1113671T1 (el) 2016-07-27
CN105687190A (zh) 2016-06-22
RU2662560C2 (ru) 2018-07-26
PH12014501629A1 (en) 2016-01-18
CA2894860C (en) 2018-11-06
JP2016128442A (ja) 2016-07-14
HUE037938T2 (hu) 2018-09-28
IL256313A (en) 2018-02-28
PH12018500023A1 (en) 2019-07-15
MY159826A (en) 2017-02-15
PE20110711A1 (es) 2011-10-11
US20140148479A1 (en) 2014-05-29
PL2889033T3 (pl) 2018-10-31
CN102281878A (zh) 2011-12-14
SG10201504102QA (en) 2015-06-29
US8815933B2 (en) 2014-08-26
CN105687191A (zh) 2016-06-22
PT2540297E (pt) 2015-08-26
TR201807944T4 (tr) 2018-06-21
KR20180011888A (ko) 2018-02-02
ZA201104044B (en) 2012-11-28
RS52583B (en) 2013-04-30
WO2010059844A1 (en) 2010-05-27
LT2889033T (lt) 2018-07-10
CL2018001420A1 (es) 2018-09-28
DK2540297T3 (en) 2015-07-13
US20140155430A1 (en) 2014-06-05
PT2889033T (pt) 2018-06-18
AU2009316557A1 (en) 2010-05-27
EP2355822A1 (en) 2011-08-17
CO6400190A2 (es) 2012-03-15
EP3357495B1 (en) 2019-12-25
US8569354B2 (en) 2013-10-29
US20110288119A1 (en) 2011-11-24
KR20140146216A (ko) 2014-12-24
NZ593467A (en) 2013-07-26
PT2355822E (pt) 2013-01-14
JP5272080B2 (ja) 2013-08-28
ECSP11011076A (es) 2011-09-30
HUE026815T2 (en) 2016-07-28
HRP20180942T1 (hr) 2018-08-10
CL2017001853A1 (es) 2018-05-11
CY1116460T1 (el) 2017-03-15
JP2020040977A (ja) 2020-03-19
IL256140A (en) 2018-02-28
CA2744278A1 (en) 2010-05-27
PH12014501629B1 (en) 2016-01-18
CY1121607T1 (el) 2020-05-29
HRP20130007T1 (hr) 2013-01-31
SI2355822T1 (sl) 2013-02-28
BRPI0922057A2 (pt) 2015-12-15
DK2889033T3 (en) 2018-07-02
ES2396300T3 (es) 2013-02-20
MY173229A (en) 2020-01-07
PL2540297T3 (pl) 2015-12-31
IL242035A0 (en) 2015-11-30
JP2013166771A (ja) 2013-08-29
RU2014122858A (ru) 2015-12-10
HRP20150711T1 (hr) 2015-08-14
HK1158520A1 (en) 2012-07-20
SMT201500167B (it) 2015-09-07
US20150265583A1 (en) 2015-09-24
EP2540297B1 (en) 2015-04-08
IL242034A (en) 2017-12-31
CA2744278C (en) 2015-09-08
IL212921A0 (en) 2011-07-31
JP2015083574A (ja) 2015-04-30
IL212921A (en) 2015-11-30
JP6223480B2 (ja) 2017-11-01
MX2011005270A (es) 2011-08-03
JP5674854B2 (ja) 2015-02-25
US20180271844A1 (en) 2018-09-27
SMT201300003B (it) 2013-05-06
SI2889033T1 (en) 2018-08-31
JP2018039818A (ja) 2018-03-15
ES2541528T3 (es) 2015-07-21
RU2532327C2 (ru) 2014-11-10
IL242034A0 (en) 2015-11-30
US20130137717A1 (en) 2013-05-30
RU2011124515A (ru) 2012-12-27
CA3017886A1 (en) 2010-05-27
EP2889033A1 (en) 2015-07-01
NZ613291A (en) 2014-11-28
ES2673016T3 (es) 2018-06-19

Similar Documents

Publication Publication Date Title
CR20110267A (es) Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
TR201908151T4 (tr) İzoindolin türevleri.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
AU2014365665A1 (en) Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
RS53033B (en) VILDAGLIPTIN AND GLIMEPIRID COMBINATIONS